Performance
Trailing returns
| 1 day |
| -1.72% | |||
| 1 week | +0.93% |
| |||
| 4 week | +1.88% |
| |||
| 3 month | +10.83% |
| |||
| YTD | +19.10% |
| |||
| 1 year | +26.83% |
| |||
| 3 years* | +15.08% |
| |||
| 5 years* | +10.56% |
| |||
| *annualized | |||||
| Best 3 month return | +55.19% | |
| Worst 3 month return | -19.75% |
Morningstar statistics
Morningstar category: Health
| Return | Risk | Rating | |
| 3 years | Below Average | Below Average |
 
|
| 5 years | Below Average | Low |
|
| 10 years | Below Average | Below Average |
|
| Overall | Below Average | Below Average |
|
Morningstar style Learn more
| Large | |||
| Mid | |||
| Small | |||
| Value | Blend | Growth |
Key statistics
| Total assets | 1.09B | |
| Front load | - | |
| Deferred load | 5.00% | |
| Expense ratio | 2.16% | |
| Management fee | - | |
| Fund family | Eaton Vance |
Asset allocation
| Cash | 0.00% | |
| Stocks | 100.02% | |
| Bonds | 0.00% | |
| Other | -0.02% |
Purchase information
| Initial | US$1,000 | |
| Additional | US$0 | |
| AIP Initial | US$1,000 | |
| AIP Additional | US$50 |
10.91+0.06(0.55%)
May 17, 4:00PM EDT
Overall Morningstar RatingTM
Description
The investment seeks long-term capital growth by investing in a worldwide and diversified portfolio of health sciences companies. The fund normally invests at least 80% of its net assets in securities of companies principally engaged in the discovery, development, production or distribution of products related to scientific advances in health care, including biotechnology, pharmaceuticals, diagnostics, managed health care and medical equipment and supplies. It concentrates (that is, invests at least 25% of its assets) its investments in medical research and the health care industry. The fund may invest up to 5% of its total assets in royalty bonds.
Fund filings (PDF) »
Fund filings (PDF) »
Asset managers:
Samuel Isaly (Started: Jul 26, 1985)
Sven Borho (Started: Jan 3, 2005)
Richard Klemm (Started: Jan 3, 2005)
Geoffrey Hsu (Started: Jan 3, 2005)
Trevor Polischuk (Started: Jan 3, 2005)
Samuel Isaly (Started: Jul 26, 1985)
Sven Borho (Started: Jan 3, 2005)
Richard Klemm (Started: Jan 3, 2005)
Geoffrey Hsu (Started: Jan 3, 2005)
Trevor Polischuk (Started: Jan 3, 2005)
Two International Place
Risk
| 1 year | 3 years | 5 years | 10 years | ||
| Alpha* | 5.29 | 6.42 | 8.98 | 3.18 | |
| Beta* | 0.92 | 0.62 | 0.54 | 0.57 | |
| Mean annual return | 1.69 | 1.08 | 0.94 | 0.77 | |
| R-squared* | 70.78 | 62.69 | 49.27 | 41.32 | |
| Standard deviation | 13.61 | 13.07 | 15.82 | 14.19 | |
| Sharpe ratio | 1.49 | 0.99 | 0.69 | 0.53 | |
| * Against standard index | |||||
Top 10 holdings
| Security | Net Assets | |
| Roche Holding AG (RHHVF) | 6.19% | |
| Sanofi (SAN) | 5.43% | |
| Gilead Sciences Inc (GILD) | 5.25% | |
| Pfizer Inc (PFE) | 5.10% | |
| HCA Holdings Inc (HCA) | 4.24% | |
| Bristol-Myers Squibb Company (BMY) | 3.69% | |
| Amgen Inc (AMGN) | 3.41% | |
| Merck & Co Inc (MRK) | 3.08% | |
| Mylan Inc (MYL) | 2.94% | |
| ONO Pharmaceutical Co., Ltd. (4528) | 2.80% |